Diurnal Share Discussion Threads

[lovewinshatelosses] 12/7/2021 17:54

This is a nervous market. DNL is doing fine, as far as I can see, but I think it might take a lot more time than many of us anticipated (myself included) to get this to a quid and beyond. Any delays or set backs and it will get hammered, but there is no cause for concern, unless I have missed something, which I do not think I have. GLA.

[aimmafia] 12/7/2021 17:28

When will we start actually receiving money from anywhere?

[glasswala] 12/7/2021 17:16

China sales targets when hit will give $28m plus high tier royalties. So we just have to wait.

[glasswala] 12/7/2021 11:08

A slow boat to China is quicker than this shares price trajectory. I mean what more is needed to get this going.The BOD have given reasonable and timely updates and gotten the necessary approval both from EU and UK the final one is US Phase 3 trial and a small trial in China if i am not mistaken. I think we need sales figures and profitability b4 this really motors on.

[aimmafia] 12/7/2021 09:29

Madness....

[simon_64] 12/7/2021 09:25

I am with you there small crow.

[david gruen] 12/7/2021 07:30

12/07/2021 7:00am
UK Regulatory (RNS & others)

Diurnal (LSE:DNL)
Intraday Stock Chart

Monday 12 July 2021

RNS Number : 8385E

Diurnal Group PLC

12 July 2021

Diurnal Group plc

("Diurnal" or the "Company")

Diurnal receives agreement from US FDA on Special Protocol Assessment for Chronocort(R)

Pivotal Phase 3 trial expected to commence in the US in H2 2021

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that the US Food and Drug Administration (FDA) has agreed a Special Protocol Assessment (SPA) for Chronocort(R) (modified-release hydrocortisone) for the design, endpoints and statistical analysis approach of a pivotal study of Chronocort(R) for the treatment for Congenital Adrenal Hyperplasia (CAH) in the US. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that would support the regulatory submission for drug approval.

The pivotal study is entitled "A randomised, double-blind, active-controlled, Phase 3 study of Chronocort(R) compared with immediate-release hydrocortisone replacement therapy in participants aged 16-years and over with Congenital Adrenal Hyperplasia (CAH)" - CONnECT - and is anticipated to start during H2 2021. Study start-up activities have already been commenced by the Company to enable a timely initiation and recruitment of up to 150 subjects with CAH who will be treated for a period of 52 weeks.

Chronocort(R) is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition, caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase. Diurnal holds the relevant Orphan Drug Designation for use of Chronocort(R) in CAH in the US. Approximately two-thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect a total of approximately 16,000 patients in the US.

Martin Whitaker, Chief Executive Officer of Diurnal, commented:

"We are pleased to have concluded a series of positive discussions with the FDA around the design of our pivotal Chronocort(R) study to support a regulatory submission for marketing approval in the US. During the first half of 2021 the Diurnal team has been working hard to complete the required preparation activities for this trial and we look forward to starting this study as soon as possible."

[best1467] 12/7/2021 07:22

Yet another positive achieved will greatly increase the likelihood of approval and time to market would expect a positive response from the market

[small crow] 09/7/2021 19:31

It's only a feeling from watching the share action but I suspect that a bigger co or hedgie has been accumulating shares for months and will fairly soon make an offer. If so I reckon we might expect £1.50. Certainly not selling.

[simon_64] 09/7/2021 14:27

Agree best.

[best1467] 09/7/2021 14:12

Happens all the time but they have delivered on every target in the last 2/3 years its the market response thats the problem.
Its extremely frustrating with the progress achieved to still have a Mcap of 100M hopefully the results will start to see some meaningful growth in sales with Alltwen new countries on stream and chroncort to follow shortly.My first purchase was in the low 30p range and with the progress since its amazing that we are only at the low 60p range but IMHO patience will win out eventually .

[glasswala] 09/7/2021 12:55

No wonder they were not buying shares - They were getting loads free of charge.

[s34icknote] 09/7/2021 12:33

If you can get a winner elsewhere then use profits on this one !!!That's what I'm hoping for !!!Fingers crossed on angle fda !

[aimmafia] 09/7/2021 12:31

This is madness how undervalued we are now....

[mufprat] 09/7/2021 11:34

Directors selling off shares to pay for free shares which arguably have not been earned.

[aimmafia] 08/7/2021 15:00

This will turn very soon.... But yes I didnt take the shares as I knew it would drop below.

[s34icknote] 08/7/2021 10:23

Little top up 33k trade

[aimmafia] 08/7/2021 09:33

Have they now reduced the spread to get the blues flowing? Please, mms, help us out here zzzzzzzz

[aimmafia] 07/7/2021 09:08

That will have no positives on the Shareprice that RNS

[utyinv] 07/7/2021 08:41

No, but we nay get some news by 14th Sept:

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2021 on Tuesday, 14 September 2021.

[aimmafia] 07/7/2021 07:57

So no insight to the webinar?

[small crow] 06/7/2021 23:41

I consulted the Dalai Llama and he said " Like the waterfall that waits for the salmon through the autumn, patience needed." Will that do?

[aimmafia] 06/7/2021 21:20

It would be nice to have some insight if anyone has any info

[s34icknote] 06/7/2021 20:41

Any one get anywhere with webinar ?